Immunohistochemical comparison of ovarian and uterine endometrioid carcinoma, endometrioid carcinoma with clear cell change, and clear cell carcinoma

American Journal of Surgical Pathology

Volumn 39, Issue 8, 2015, Pages 1061-1069

  Lim, Diana ^a   Ip, Philip P C ^b   Cheung, Annie N Y ^b   Kiyokawa, Takako ^c   Oliva, Esther ^d  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

clear cell; endometrial carcinoma; endometrioid; endometrioid with clear cells; immunohistochemistry; ovarian carcinoma

Indexed keywords

ARID1A PROTEIN, HUMAN; ASPARTIC PROTEINASE; ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 1BETA; HNF1B PROTEIN, HUMAN; NAPSA PROTEIN, HUMAN; NUCLEAR PROTEIN; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR; TUMOR MARKER;

CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; HONG KONG; HUMAN; IMMUNOHISTOCHEMISTRY; JAPAN; MULTICENTER STUDY; OVARY TUMOR; PATHOLOGY; PREDICTIVE VALUE; UNITED STATES;

ASPARTIC ACID ENDOPEPTIDASES; BOSTON; CARCINOMA, ENDOMETRIOID; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; FEMALE; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HONG KONG; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84938125462     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000436     Document Type: Article

References (60)

1. Cirisano FD Jr, Robboy SJ, Dodge RK, et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol. 1999;74:385-394.
2. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23:41-44.
3. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584-2589.
4. Duska LR, Garrett L, Henretta M, et al. When "never-events" occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gynecol Oncol. 2010;116: 374-377.
5. Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol. 1996;60:412-417.
6. Matsuura Y, Robertson G, Marsden DE, et al. Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol. 2007;104:406-410.
7. Tan DS, Miller RE, Kaye SB. New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. Br J Cancer. 2013;108:1553-1559.
8. DeLair D, Han G, Irving JA, et al. HNF-1beta in ovarian carcinomas with serous and clear cell change. Int J Gynecol Pathol. 2013;32:541-546.
9. Kurman R. Tumors of the ovary. In: Kurman RJ, Carcangiu ML, Herrington CS, et al, eds. WHO Classification of Tumours of Female Reproductive Organs. Lyons: IARC Press; 2014:11-83.
10. Nagle CM, Olsen CM, Webb PM, et al. Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors. Eur J Cancer. 2008;44:2477-2484.
11. Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol. 2003;189:280-294.
12. Prowse AH, Manek S, Varma R, et al. Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer. 2006;119:556-562.
13. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11:6422-6430.
14. Guirguis A, Elishaev E, Oh SH, et al. Use of gene expression profiles to stage concurrent endometrioid tumors of the endometrium and ovary. Gynecol Oncol. 2008;108:370-376.
15. Kobel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29:203-211.
16. Fadare O, Parkash V, Dupont WD, et al. The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists: an assessment of interobserver variability and associated morphologic features. Am J Surg Pathol. 2012;36:1107-1118.
17. Han G, Gilks CB, Leung S, et al. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases. Am J Surg Pathol. 2008;32:955-964.
18. Han G, Sidhu D, Duggan MA, et al. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod Pathol. 2013;26:1594-1604.
19. Silva EG, Young RH. Endometrioid neoplasms with clear cells: a report of 21 cases in which the alteration is not of typical secretory type. Am J Surg Pathol. 2007;31:1203-1208.
20. Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer. 1982;49:1511-1523.
21. Clizer EE, Glassman JA. Hypernephroid endometrial carcinoma: case report. J Urol. 1971;106:366-367.
22. Silverberg SG, De Giorgi LS. Clear cell carcinoma of the endometrium. Clinical, pathologic, and ultrastructural findings. Cancer. 1973;31:1127-1140.
23. Kurman RJ, Scully RE. Clear cell carcinoma of the endometrium: an analysis of 21 cases. Cancer. 1976;37:872-882.
24. Bohn S, Thomas H, Turan G, et al. Distinct molecular and morphogenetic properties of mutations in the human HNF1beta gene that lead to defective kidney development. J Am Soc Nephrol. 2003;14:2033-2041.
25. Coffinier C, Gresh L, Fiette L, et al. Bile system morphogenesis defects and liver dysfunction upon targeted deletion of HNF1beta. Development. 2002;129:1829-1838.
26. Igarashi P, Shao X, McNally BT, et al. Roles of HNF-1beta in kidney development and congenital cystic diseases. Kidney Int. 2005;68:1944-1947.
27. Pontoglio M. Hepatocyte nuclear factor 1, a transcription factor at the crossroads of glucose homeostasis. J Am Soc Nephrol. 2000;11(suppl 16):S140-S143.
28. Schwartz DR, Kardia SL, Shedden KA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002;62:4722-4729.
29. Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003;163:2503-2512.
30. Kato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol. 2006;19:83-89.
31. Yamamoto S, Tsuda H, Aida S, et al. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol. 2007;38:1074-1080.
32. Fadare O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. Appl Immunohistochem Mol Morphol. 2012;20:580-587.
33. Kenny SL, McBride HA, Jamison J, et al. Mesonephric adenocarcinomas of the uterine cervix and corpus: HPV-negative neoplasms that are commonly PAX8, CA125, and HMGA2 positive and that may be immunoreactive with TTF1 and hepatocyte nuclear factor 1- beta. Am J Surg Pathol. 2012;36:799-807.
34. Kim L, Liao J, Zhang M, et al. Clear cell carcinoma of the pancreas: histopathologic features and a unique biomarker: hepatocyte nuclear factor-1beta. Mod Pathol. 2008;21:1075-1083.
35. Kobel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and highgrade serous carcinoma of the ovary. Am J Surg Pathol. 2009;33: 14-21.
36. Hoang LN, Han G, McConechy M, et al. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma- diagnostic utility of HNF-1beta and oestrogen receptor. Histopathology. 2014;64:585-596.
37. Kao YC, Lin MC, Lin WC, et al. Utility of hepatocyte nuclear factor-1beta as a diagnostic marker in ovarian carcinomas with clear cells. Histopathology. 2012;61:760-768.
38. Brasch F, Ochs M, Kahne T, et al. Involvement of napsin A in the C- and N-terminal processing of surfactant protein B in type-II pneumocytes of the human lung. J Biol Chem. 2003;278:49006-49014.
39. Woischnik M, Bauer A, Aboutaam R, et al. Cathepsin H and napsin A are active in the alveoli and increased in alveolar proteinosis. Eur Respir J. 2008;31:1197-1204.
40. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010;41:20-25.
41. Ordonez NG. Napsin A expression in lung and kidney neoplasia: a review and update. Adv Anat Pathol. 2012;19:66-73.
42. Turner BM, Cagle PT, Sainz IM, et al. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med. 2012;136: 163-171.
43. Fadare O, Desouki MM, Gwin K, et al. Frequent expression of napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility. Am J Surg Pathol. 2014;38:189-196.
44. Kadivar M, Boozari B. Applications and limitations of immunohistochemical expression of "Napsin-A" in distinguishing lung adenocarcinoma from adenocarcinomas of other organs. Appl Immunohistochem Mol Morphol. 2013;21:191-195.
45. Skirnisdottir I, Bjersand K, Akerud H, et al. Napsin A as a marker of clear cell ovarian carcinoma. BMC Cancer. 2013;13:524.
46. Yamashita Y, Nagasaka T, Naiki-Ito A, et al. Napsin A is a specific marker for ovarian clear cell adenocarcinoma. Mod Pathol. 2015;28:111-117.
47. Kounelis S, Kapranos N, Kouri E, et al. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol. 2000;13:379-388.
48. Lax SF, Pizer ES, Ronnett BM, et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol. 1998;29:551-558.
49. Reid-Nicholson M, Iyengar P, Hummer AJ, et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol. 2006;19:1091-1100.
50. Zannoni GF, Morassi F, Prisco MG, et al. Clinicopathologic and immunohistochemical features of ovarian clear cell carcinomas in comparison with type I and type II tumors. Int J Gynecol Pathol. 2012;31:507-516.
51. Dinulescu DM, Ince TA, Quade BJ, et al. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med. 2005;11:63-70.
52. Kurman RJ, Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008;27:151-160.
53. Guan B, Mao TL, Panuganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol. 2011;35:625-632.
54. Jones S, Li M, Parsons DW, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat. 2012;33:100-103.
55. Jones S, Wang TL, Shih Ie M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330:228-231.
56. Lowery WJ, Schildkraut JM, Akushevich L, et al. Loss of ARID1Aassociated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer. 2012;22: 9-14.
57. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010; 363:1532-1543.
58. Maeda D, Mao TL, Fukayama M, et al. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci. 2010;11:5120-5128.
59. Ayhan A, Mao TL, Seckin T, et al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer. 2012;22:1310-1315.
60. Yamamoto S, Tsuda H, Takano M, et al. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol. 2012;25:615-624.